Axsome Therapeutics (AXSM) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AXSM Axsome Therapeutics

Watchlist

103.110
-0.780-0.75%

Close Jan 24 16:00 ET

103.110
0.0000.00%

Post 20:01 ET

5.00BMarket Cap-15.67P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $139
Moomoo NewsJan 22 21:32 ET · Ratings
Axsome Therapeutics (AXSM) Gets a Buy From RBC Capital
TipRanksJan 22 20:59 ET · Ratings
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18
GlobeNewswireJan 22 07:00 ET
Express News | Axsome Therapeutics Inc : RBC Cuts Target Price to $139 From $140
ReutersJan 22 00:22 ET
Axsome Therapeutics Participates in a Conference Call With William Blair
TipRanksJan 21 15:55 ET
Express News | Axsome Therapeutics Shares Are Trading Higher. HC Wainwright & Co. Reiterated a Buy Rating on the Stock
BenzingaJan 21 14:57 ET

Comments

Clintzilla

Oct 12, 2024 14:13

$Axsome Therapeutics (AXSM.US)$ wonder what the insitutional ownership was when it went from 2 to 110 lol

Vincenttpc

Sep 25, 2024 08:07

$Axsome Therapeutics (AXSM.US)$ why the sudden drop?

Meltyy

Mar 18, 2024 03:21

FDA Development Paths

$Pfizer (PFE.US)$ $Novo-Nordisk A/S (NVO.US)$ $Axsome Therapeutics (AXSM.US)$ $Macrogenics (MGNX.US)$
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...

Meltyy

Mar 4, 2024 03:54

🎯 Ph 3 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$ Phase 3
$Aquestive Therapeutics (AQST.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$Johnson & Johnson (JNJ.US)$ Phase 3

Meltyy

Feb 26, 2024 00:34

4 Bio Readouts To Watch This Qtr

1. $Annovis Bio (ANVS.US)$
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics (AXSM.US)$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics (GTHX.US)$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics (CRNX.US)$
• Ph 3 data (PATHFND...

AXSM Axsome Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks